Orlistat

Orlistat is an anti-obesity drug and the first of the lipase inhibitor class to reach the market ^[1]. Unlike appetite suppressants that act on the brain, orlistat works locally in the digestive tract and is only minimally absorbed into the bloodstream ^[1]. Chemically it is a stable, saturated derivative of lipstatin, a natural compound produced by the bacterium Streptomyces toxytricini ^[1].

The drug was developed by Hoffmann-La Roche and received United States approval in 1999 as the prescription medicine Xenical ^[1][2]. In 2007 a lower-strength version, Alli, became the first weight-loss drug cleared for over-the-counter sale in the United States. Orlistat is now available as a generic and appears on lists of established obesity treatments alongside newer agents ^[1].

Orlistat is used, together with a reduced-calorie diet, to treat obesity and to help maintain weight loss ^[1][2]. In controlled trials it produces modestly greater weight loss than diet alone, on the order of a few kilograms more per year, and helps prevent the weight regain that often follows dieting ^[2]. Beyond the scale, studies have found improvements in blood cholesterol, blood sugar, and blood pressure, and a large trial showed that adding orlistat to lifestyle changes reduced the risk of developing type 2 diabetes in obese people ^[3]. These benefits led to its use as an adjunct in patients whose obesity carries added health risks ^[1].

Orlistat is sold as capsules in prescription strength (Xenical) and a lower over-the-counter strength (Alli) ^[1]. Its side effects follow directly from its mechanism: because unabsorbed fat continues into the bowel, users can experience oily or loose stools, urgency, gas with discharge, and similar gastrointestinal effects, which tend to be worse with high-fat meals and to lessen over time ^[1][2]. By blocking fat absorption it can also reduce uptake of fat-soluble vitamins, so a daily multivitamin is commonly recommended ^[1]. It is generally reserved for people committed to accompanying diet and lifestyle changes ^[1].

Orlistat is available over the counter and by prescription. Its side effects follow directly from unabsorbed fat in the gut; oily or loose stools, urgent bowel movements, gas with oily spotting, and more frequent stools, all worse after fatty meals and usually milder as people cut dietary fat. Because it blocks fat absorption it also reduces uptake of the fat-soluble vitamins A, D, E, and K, so a bedtime multivitamin is advised. It can lower the absorption of some important medicines including cyclosporine, levothyroxine, certain antiseizure drugs, and warfarin, which should be separated in time. Rare cases of serious liver injury have been reported.

Orlistat inhibits gastric and pancreatic lipase in the gut lumen, and almost every interaction it has follows from that: fat is left unabsorbed, and anything needing fat to be absorbed goes with it.

Cyclosporine is the sharpest example. Levels fall substantially when the two are taken together, enough that transplant rejection has been reported, and the same absorption problem applies to levothyroxine and to amiodarone. Antiretroviral failure has been described in case reports, with loss of viral suppression attributed to reduced drug uptake.

Warfarin is a two sided problem. Orlistat reduces absorption of vitamin K along with dietary fat, so the INR can move unpredictably rather than in one direction.

The fat soluble vitamins A, D, E and K are reduced across the board, and antiepileptics including lamotrigine and valproate have been associated with breakthrough seizures. None of this involves enzyme inhibition; orlistat is barely absorbed, and the interaction happens in the gut.

Checking a whole stack? Run it through interactions + stacks.

Orlistat originates from lipstatin, a natural pancreatic lipase inhibitor isolated from the soil bacterium Streptomyces toxytricini; chemists at Hoffmann-La Roche hydrogenated and stabilized this fragile natural product to create the more robust saturated derivative tetrahydrolipstatin, which became orlistat. Roche advanced the compound through development in the late 1980s and 1990s as a novel, gut-restricted approach to obesity that avoided the appetite-suppressing stimulants that had defined earlier weight-loss drugs.

The prescription product Xenical received United States Food and Drug Administration approval in 1999 for obesity management, and it went on to be marketed in many countries. In 2007 the FDA cleared a lower-strength version, Alli, for over-the-counter sale, making it the first weight-loss medicine approved for nonprescription use in the United States, distributed by GlaxoSmithKline. Orlistat remains one of a small number of agents specifically indicated for long-term weight management and one of the few that acts entirely within the digestive tract.

Orlistat holds a respected niche as a mechanistically distinct weight-loss option; because it works in the gut and is barely absorbed, it sidesteps the cardiovascular and central-nervous-system concerns that ended the careers of many appetite-acting diet drugs. A large network meta-analysis of FDA-approved obesity medicines confirmed that orlistat produces significantly more weight loss than placebo, with roughly 44 percent of users achieving at least 5 percent weight loss over a year.

It is valued for a long safety record, decades of use, and availability without prescription at low dose, which puts a clinically studied tool within easy reach. Its main limitation is tolerability rather than danger; the same undigested fat that drives its benefit produces the oily, urgent stools that lead some people to stop. Honestly framed, it offers modest but real weight loss that works best alongside a reduced-fat diet, and it can reduce absorption of fat-soluble vitamins, so supplementation is often advised.